MedTrace Logo

PK Study of IV Formulation of GW856553

NCT01039961 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-06-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of an IV infusion of GW856553 in healthy volunteers.

Conditions

Interventions

DRUG

losmapimod 1 mg

IV infusion

DRUG

losmapimod

IV infusion (dose to be determined based on PK from first dose)

DRUG

losmapimod 15 mg

oral, two 7.5 mg tablets

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-02
Primary Completion
2010-04-15
Completion
2010-04-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01039961 on ClinicalTrials.gov